GSK says its PD-1 inhibitor Jemperli compared favourably with Merck & Co’s Keytruda in a head-to-head trial in previously-untreated non-small cell lung cancer (NSCLC), with numerically
$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but, in fact, it comes from diminutive biotech Summit Therapeutics.
The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea's Hanmi Pharma, which origi
Just a couple of weeks after finally getting its first FDA approval for CTLA4 inhibitor Imjudo for advanced liver cancer, AstraZeneca has picked up another – and in a much larger patient po
Merck & Co's Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but was leapfrogged by Roche's Tecentriq in the early-stage, adjuvant trea
Amgen now has regulatory approval on both sides of the Atlantic for Lumykras, the culmination of many years of effort to bring a drug to market that inhibits KRAS – a cancer target that for
Sales of AstraZeneca's COVID-19 vaccine dwindled to almost nothing in the fourth quarter of 2022, contributing to a weaker-than-expected performance for the group.
Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved